<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2019.1012086</article-id><article-id pub-id-type="publisher-id">JCT-97500</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Radiation Sensitivity of &lt;i&gt;in Vitro&lt;/i&gt; Evaluation System of Pharmacokinetics in Boron Neutron Capture Therapy (BNCT) Using Three-Dimensional Artificial Human Tumor Tissue Model
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shintaro</surname><given-names>Ishiyama</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Minoru</surname><given-names>Suzuki</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, Asahiro-nishi, Kumamori, Sennan, Osaka, Japan</addr-line></aff><aff id="aff1"><addr-line>Faculty of Science and Technology, Graduate School of Science and Technology, Hirosaki University, Bunkyo, Hirosaki, Aomori, Japan</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>12</month><year>2019</year></pub-date><volume>10</volume><issue>12</issue><fpage>1025</fpage><lpage>1035</lpage><history><date date-type="received"><day>9,</day>	<month>November</month>	<year>2019</year></date><date date-type="rev-recd"><day>27,</day>	<month>December</month>	<year>2019</year>	</date><date date-type="accepted"><day>30,</day>	<month>December</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  One of the important matters that must be determined in advance when performing BNCT treatment is the optimization of neutron irradiation time and dose. In this article, following the previous article (2.52 &#215; 10
  <sup>12</sup>
   
  n/cm<sup>2</sup>) (Case 1), double irradiation (5.04 &#215; 10<sup>12</sup>
   
  n/cm<sup>2</sup>) was further performed (Case 2) by verifying the radiation sensitivity performance of the artificial tumor tissue NHDF3D/BxPC3 and the possibility of evaluating the optimum neutron dose required for treatment was examined. As a result, although the radiation damage rate in the normal tissue NHDF3D and the tumor tissue BxPC3 increased in proportion to the irradiation dose due to heavy irradiation in Case 1 or more, the increase in the damage rate in the normal tissue exceeded the tumor tissue. Furthermore, the tumor/normal tissue damage ratio T/N ratio showed the maximum value in Case 1, and the dose ratio in Case 2 with a higher dose showed a tendency to decrease.
   
  From the above experimental facts, it was shown that irradiation dose optimization is possible to some extent by an evaluation method using an artificial tumor tissue.
 
</p></abstract><kwd-group><kwd>Boron Neutron Capture Therapy (BNCT)</kwd><kwd> Boronophenylalanine  (&lt;sup&gt;10&lt;/sup&gt;BPA)</kwd><kwd> Artificial Human Tumor Tissue Model</kwd><kwd> Cell Accumulation  Method</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>In the previous paper [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>], the authors made a bilayer 3D artificial tumor tissue (BxPC3/NHDF3D) using human pancreatic cancer cell line BxPC3 and normal human dermal-derived fibroblast NHDF3D, and pharmacokinetic study for 10BPA-BNCT treatment [<xref ref-type="bibr" rid="scirp.97500-ref2">2</xref>] - [<xref ref-type="bibr" rid="scirp.97500-ref10">10</xref>] by neutron irradiation from reactor Went. As a result, optical observation of the irradiated tissue gave a T/N ratio of 3.19 at a neutron dose of 2.52 &#215; 10<sup>12</sup> n/cm<sup>2</sup>, indicating the effectiveness of the BNCT pharmacokinetics test using 3D artificial tissue [<xref ref-type="bibr" rid="scirp.97500-ref11">11</xref>] - [<xref ref-type="bibr" rid="scirp.97500-ref16">16</xref>].</p><p>On the other hand, what is important in BNCT treatment of tumor patients is to secure the accumulation in the tumor affected area after the boron drug administration and to optimize the irradiation dose during the treatment.</p><p>Therefore, in this paper, we examined the applicability of the 3D artificial tumor tissue used in the previous paper [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>] as a testing technique for optimizing the radiation dose at the time of BNCT treatment while verifying the sensitivity performance to radiation dose.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Cells, Reagents and Instruments</title><p>Normal human dermal-derived fibroblast (NHDFs) and red fluorescent protein (RFP) -labeled human pancreatic cancer cell line BxPC3 used in the experiment were purchased from LONZA (Walkersville, MD) and Anti-Cancer Japan (Ibaraki, Japan), respectively. Dulbecco’s modified Eagle’s medium (DMEM) (Wako, Osaka, Japan) containing 10% fetal bovine serum (FBS) (Nichirei, Tokyo, Japan) was used to proliferate cells prior to construction of the tumor tissue model. The cells were cultivated at 37˚C, 5% carbon dioxide. Bovine plasma-derived fibronectin (FN) and porcine skin gelatin (G) were purchased from Sigma-Aldrich (St. Louis, MO) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan), respectively. Transwell inserts with porous polyester bottom (pore size: 0.4 &#181;m) for 12-well culture plate (12 mm diameter, 112 mm<sup>2</sup> area, cat. No. 3401) were purchased from CORNING Inc. (New York, NY). The boron drug <sup>10</sup>BPA (boronophenylalanine; C<sub>9</sub>H<sub>12</sub>BNO<sub>4</sub>, molecular weight 209.01, fructose complex) was kindly gifted from Interpharma Praha, a.s. (Komorany, Czechia). A solid-state nuclear track detector CR-39, an optical plastic material with composition C<sub>12</sub>H<sub>18</sub>O<sub>7</sub> [<xref ref-type="bibr" rid="scirp.97500-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref8">8</xref>], was purchased from Cokin (Tokyo, Japan) [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p></sec><sec id="s2_2"><title>2.2. Preparation of in Vitro Human Three-Dimensional Tumor Tissue Model</title><p>Human three-dimensional tumor tissue was prepared by cell accumulation method [<xref ref-type="bibr" rid="scirp.97500-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref14">14</xref>]. First, connective tissue-like structures were fabricated by three-dimensional lamination of NHDFs. As shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, NHDFs are cultured under the conditions mentioned above, then ECM-nano film (about 10 nm thick) was formed on each cell surface by coating cells with fibronectin and gelatin dissolved in Tris-HCl buffer according to previously published methods</p><p>[<xref ref-type="bibr" rid="scirp.97500-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref14">14</xref>]. The cells are seeded on the transwell inserts at a density of 27.2 &#215; 10<sup>5</sup> cells/insert (8 layers) and cultured under the conditions of 5% carbon dioxide at 37˚C for 12 to 24 hours. We regarded this connective tissue-like structure as an artificial human normal tissue model, termed as NHDF3D [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p><p>Next, RFP-labeled BxPC3 cells which have been cultured and proliferated were collected by trypsin treatment, washed, and uniformly seeded on the upper surface of NHDF3D at a density of 300 cells/mm<sup>2</sup>, then further cultured for 24 hours under the above culture conditions. BxPC3 cells proliferated on the surface of NHDF3D forming the groups with a flat shape. We regarded this cancer-loaded NHDF3D as an artificial human tumor tissue model, termed as NHDF3D/BxPC3. In the present study, one case of NHDF3D and three cases of NHDF3D/BxPC3 were prepared by the methods mentioned above and were used for the experiments.</p></sec><sec id="s2_3"><title>2.3. BPA Immersion Treatment and Fixation</title><p>The boronophenylalanine (BPA) solution (3% w/v) was diluted to a concentration of 40 ppm with DMEM containing 10% FBS. This is referred to as a BPA treatment solution. After removing the culture solution of NHDF3D or NHDF3D/BxPC3, 750 μl of BPA treatment solution was added, and incubated for 2 hours (BPA exposure) under conditions of 5% carbon dioxide at 37˚C. After that, the BPA treatment solution was removed and the tissues were washed 3 times with 0.01 M phosphate buffered saline (PBS, pH 7.3). Subsequently, the tissues were fixed by 4% paraformaldehyde/0.1 M phosphate buffer (pH 7.3) for 30 minutes at room temperature shading the light. After the fixation, the cellular nucleus was stained by 4’,6-diamidino-2-phenylindole (DAPI) [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p></sec><sec id="s2_4"><title>2.4. Observation of BxPC3 cell Distribution on the Artificial Tissues</title><p>After the fixation, three holes were provided on the tissue using an 18 G injection needle in order to provide alignment marks. Then the top surface of NHDF3D/BxPC3 was observed by fluorescence microscope BZ-X700 (Keyence, Osaka, Japan). The distribution of BxPC3 cells was visualized as a fluorescence image by RFP excitation. A low magnification image including the entire tissue and high magnification images of various parts of each tissue were respectively obtained. A fluorescence image of NHDF3D was also obtained as a control [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p></sec><sec id="s2_5"><title>2.5. Neutron Irradiation Experiment</title><p>The above-mentioned NHDF3D or NHDF3D/BxPC3 in the transwell inserts were cut out with a knife together with the polyester base, mounted on the solid track detector CR-39 [<xref ref-type="bibr" rid="scirp.97500-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.97500-ref8">8</xref>] with close contact, and used as a sample for track image acquisition (<xref ref-type="fig" rid="fig1">Figure 1</xref>(d)). Irradiation experiments using these samples were conducted at the Heavy Water Neutron Irradiation Facility of Kyoto University Reactor (KUR), and irradiation was performed for 60 minutes under an irradiation flux of 1.4 &#215; 10<sup>9</sup> n/cm<sup>2</sup>/s (total flux = 4.5 &#215; 10<sup>12</sup> n/cm<sup>2</sup>). After the neutron irradiation, the above sample was etched (6N NaOH, 70˚C &#215; 2 hours) to visualize the α-ray/recoiled Li particle tracks generated on the CR-39 surface [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p></sec><sec id="s2_6"><title>2.6. Analysis of α-Ray/Recoiled Li Particle Track Images</title><p>The α-ray/recoiled Li particle track image of etched CR-39 was taken using the bright field function of the fluorescence microscope BZ-X700. A low magnification image including the entire tissue mount and 10 random high magnification images were obtained respectively, and the following analysis was performed.</p><p>1) The whole tissue images of fluorescent BxPC3 cell distribution and the α-ray/ recoiled Li particle track distribution were compared referring to the position of three-hole markers, and the relationship of these distributions was observed.</p><p>2) Alpha-ray/recoiled Li particle tracks in the high magnification images were regarded as the particles, and quantitatively analyzed by using software FIJI (https://fiji.sc). Briefly, after binarizing the image, the tracks with more than 4 μm diameter were detected, and their number per unit area (0.01 mm<sup>2</sup>) and the track size were measured. A significant difference between the data from the artificial normal tissue model (NHDF3D) and artificial tumor tissue model (NHDF3D/BxCP3) was confirmed using student t test [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p></sec></sec><sec id="s3"><title>3. Results and Discussions</title><sec id="s3_1"><title>3.1. Distribution of the BxPC3 Cells and Alpha-Ray/Recoiled Li Particle Tracks on the Tissue Models</title><p>Low-magnification images of NHDF3D and NHDF3D/BxPC3 (three cases) detecting RFP fluorescence were shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>(a) (NHDF3D) and Figures 2(b)-(d) (NHDF3D/BxPC3) before irradiation. Although the BxPC3 cells (Figures 2(b)-(d)) were seeded over the artificial tissue (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)) in regular cell concentration, slight heterogeneity of cell distribution was observed after the cultivation for 24 hours.</p><p>The α-ray/recoiled Li particle tracks in corresponded parts of Figures 2(a)-(d) were shown in Figures 3(a)-(d). The marked #1 - #12 in the figure are measurement points that have been observed by high-magnification optical observation in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p><p><xref ref-type="fig" rid="fig4">Figure 4</xref> group (a) (3DNHDF) and group (b) (NHDF3D/BxPC3), and <xref ref-type="fig" rid="fig4">Figure 4</xref> group (c) (d) (NHDF3D/BxPC3) showed the distribution of α-ray/recoiled Li particle tracks in 3DNHDF and NHDF3D/BxPC3, respectively.</p><p>In these figures, the α-ray/recoiled Li particle tracks were observed as small dots at #1 - #12, reflecting the intensity of the emission. These tracks distribution and density at different observation points in each tissue are approximated for each group. This means that the α-ray/recoiled Li particle damage occurs almost uniformly in each tissue.</p><p>Since the contrast between NHDF3D (<xref ref-type="fig" rid="fig4">Figure 4</xref>(a)) and NHDF3D/BxPC3</p><p>(<xref ref-type="fig" rid="fig4">Figure 4</xref>(b) and <xref ref-type="fig" rid="fig4">Figure 4</xref>(c) <xref ref-type="fig" rid="fig4">Figure 4</xref>(d)) was obvious, the BxPC3 cells-dependent incorporation of <sup>10</sup>B resulting the α-ray/recoiled Li particle emission was clearly detected in this system [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p></sec><sec id="s3_2"><title>3.2. Radiation Sensitivity of NHDF3D and NHDF3D/BxCP3</title><p>Here, we verified the suitability as a tool to determine the dose optimization during BNCT treatment by using NHDF3D/BxPC3.</p><p>To investigate detailed α-ray/recoiled Li particle track density in NHDF3D and NHDF3D/BxCP3 samples, high magnification images of α-ray/recoiled Li particle tracks on CR-39 [<xref ref-type="fig" rid="fig5">Figure 5</xref>(A) <xref ref-type="fig" rid="fig5">Figure 5</xref>(B) and <xref ref-type="fig" rid="fig5">Figure 5</xref>(a’) <xref ref-type="fig" rid="fig5">Figure 5</xref>(b’), photo] were quantitatively analyzed. Here, <xref ref-type="fig" rid="fig5">Figure 5</xref>(a’) <xref ref-type="fig" rid="fig5">Figure 5</xref>(b’) correspond to <xref ref-type="fig" rid="fig4">Figure 4</xref>(a) and <xref ref-type="fig" rid="fig4">Figure 4</xref>(c), respectively. <xref ref-type="fig" rid="fig5">Figure 5</xref>(A) and <xref ref-type="fig" rid="fig5">Figure 5</xref>(B) show α-ray/recoiled Li particle tracks observed in NHDF3D and NHDF3D/BxPC3, when irradiated with Case 1 (2.52 &#215; 10<sup>12</sup>) [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>] and <xref ref-type="fig" rid="fig5">Figure 5</xref>(a’) <xref ref-type="fig" rid="fig5">Figure 5</xref>(b’) with Case 2 (4.5 &#215; 10<sup>12</sup> n/cm<sup>2</sup> neutron dose), respectively. <xref ref-type="table" rid="table1">Table 1</xref> shows the results of measuring the density of α-ray/recoiled Li particle tracks in the unit area (0.01 mm<sup>2</sup>) in Case 1 and Case 2.</p><p>There is a clear difference in track density between the two, and it can be seen that the higher the neutron irradiation amount, the higher the track density. Similarly, when the track density of NHDF3D/BxPC3 was compared between <xref ref-type="fig" rid="fig5">Figure 5</xref>(B) and <xref ref-type="fig" rid="fig5">Figure 5</xref>(b’), it was found that the track density was high at the high dose NHDF3D/BxPC3.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> α-ray/recoiled Li particle tracks density (counts/0.01 mm<sup>2</sup>), and T/N ratio of NHDF3D/BxPC3</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Cells</th><th align="center" valign="middle" >Case 1 [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>]</th><th align="center" valign="middle" >Case 2</th><th align="center" valign="middle" >Case 2/Case 1</th></tr></thead><tr><td align="center" valign="middle" >NHDF3D</td><td align="center" valign="middle" >51.52</td><td align="center" valign="middle" >127.5</td><td align="center" valign="middle" >2.48</td></tr><tr><td align="center" valign="middle" >BxPC3(1)</td><td align="center" valign="middle" >81.10</td><td align="center" valign="middle" >146.2</td><td align="center" valign="middle" >1.80</td></tr><tr><td align="center" valign="middle" >BxPC3(2)</td><td align="center" valign="middle" >87.68</td><td align="center" valign="middle" >140.3</td><td align="center" valign="middle" >1.60</td></tr><tr><td align="center" valign="middle" >BxPC3(3)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >137.9</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >T/N</td><td align="center" valign="middle" >1.63</td><td align="center" valign="middle" >1.11</td><td align="center" valign="middle" >-</td></tr></tbody></table></table-wrap><p>The track density increases as the irradiation dose increases in this way, meaning that <sup>10</sup>B absorbed in the sample remains in the tissue in an unreacted state even after neutron irradiation for a short time of about 30 minutes [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>].</p><p><xref ref-type="fig" rid="fig6">Figure 6</xref> shows the relationship between neutron irradiation dose (n/cm<sup>2</sup>) and track density (counts/0.01 mm<sup>2</sup>). According to this, the increase rate of NHDF3D and BxPC3 is different with the increase of the irradiation amount, and the increase rate of the track density of NHDF3D is remarkable. On the other hand, it can be seen that the increase rate of BxPC3 is almost saturated, however, in Case 2, the rate of increase is similar to that of normal cells.</p><p>This means that when neutrons dose reached up to 4.25 &#215; 10<sup>12</sup> n/cm<sup>2</sup> or more, the effect of radiation damage on normal cells must be considered in addition to the original BNCT treatment effect.</p><p><xref ref-type="fig" rid="fig7">Figure 7</xref> shows the relationship between the neutron irradiation dose and the T/N ratio, where the definition of T/N ratio here is defined as the track density ratio of NHDF3D and BxPC3 in <xref ref-type="table" rid="table1">Table 1</xref>. According to this, although the T/N ratio increases as the neutron irradiation dose increases, it turns to decrease when the irradiation dose in Case 1 is exceeded. In other words, in Case 2 from the viewpoint of BNCT treatment, radiation damage to the normal tissue becomes significant and there is a possibility of over-irradiation.</p><p>In conclusion, our in vitro model of tumor tissue for BNCT demonstrated the pharmacokinetics of BPA and the efficacy of neutron irradiation by direct observation of α-ray/recoiled Li particle tracks that are corresponding to the distribution of BxPC3 cells [<xref ref-type="bibr" rid="scirp.97500-ref1">1</xref>]. Furthermore, in this paper, following the previous paper, heavy irradiation was performed using the same artificial tumor tissue. As a result, it became clear that selection of the optimal dose, which is one of the most important treatment conditions for BNCT treatment, is possible to some extent by an evaluation method using an artificial tumor tissue.</p></sec></sec><sec id="s4"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s5"><title>Cite this paper</title><p>Ishiyama, S. and Suzuki, M. (2019) Radiation Sensitivity of in Vitro Evaluation System of Pharmacokinetics in Boron Neutron Capture Therapy (BNCT) Using Three-Dimensional Artificial Human Tumor Tissue Model. Journal of Cancer Therapy, 10, 1025-1035. https://doi.org/10.4236/jct.2019.1012086</p></sec></body><back><ref-list><title>References</title><ref id="scirp.97500-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ishiyama, Asano, Y., Suzuki, M., et al. (2019) In Vitro Evaluation System of Pharmacokinetics and Irradiation Effect in Boron Neutron Capture Therapy (BNCT) Using Three-Dimentional Artificial Human Tumor Tissue Model. Journal of Cancer Therapy, 10, 835-845. https://doi.org/10.4236/jct.2019.1010071</mixed-citation></ref><ref id="scirp.97500-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Masunaga, S., Sakurai, Y., Tanaka, H., et al. (2014) The Dependency of Compound Biological Effectiveness Factors on the Type and Concentration of Administered Neutron Capture Agents in Boron Neutron Capture Therapy. Springerplus, 3, 128.  
https://doi.org/10.1186/2193-1801-3-128</mixed-citation></ref><ref id="scirp.97500-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ishiyama, S., Baba, Y., Fujii, R., Nakamura, M. and Imahori, Y. (2012) Synthesis of Lithium Nitride for Neutron Production Target of BNCT by In-Situ Lithium Deposition and Ion Implantation. Nuclear Instruments and Methods in Physics Research, 293, 42-47. https://doi.org/10.1016/j.nimb.2012.09.016</mixed-citation></ref><ref id="scirp.97500-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ishiyama, S., Baba, Y., Fujii, R., Nakamura, M. and Imahori, Y. (2013) Thermal Stability of BNC Neutron Production Target Lithium Synthesized by In-Situ Lithium Deposition and Ion Implantation. Materials Transactions, 54, 1760-1764.  
https://doi.org/10.2320/matertrans.M2013062</mixed-citation></ref><ref id="scirp.97500-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ishiyama, S. and Imahori, Y. (2014) Deterministic Parsing Model of CBE Factor for Intra-Organ 10B Distribution in Boron Neutron Capture Therapy. Journal of Cancer Therapy, 5, 1388-1398. https://doi.org/10.4236/jct.2014.514140</mixed-citation></ref><ref id="scirp.97500-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ishiyama, S., Imahori, Y., Itami, J. and Hanna, V. (2015) Determination of the Compound Biological Effectiveness (CBE) Factors Based on the Ishiyama-Imahori Deterministic Parsing Model with the Dynamic PET Technique. Journal of Cancer Therapy, 6, 759-766. https://doi.org/10.4236/jct.2015.68083</mixed-citation></ref><ref id="scirp.97500-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, M., et al. (2014) Boron Neutron Capture Therapy Outcomes for Advanced or Recurrent Head and Neck Cancer. Journal of Radiation Research, 55, 146-153.  
https://doi.org/10.1093/jrr/rrt098</mixed-citation></ref><ref id="scirp.97500-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, M., et al. (2007) First Attempt of Boron Neutron Capture Therapy (BNCT) for Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology, 37, 376-381.  
https://doi.org/10.1093/jjco/hym039</mixed-citation></ref><ref id="scirp.97500-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ichihashi, M., et al. (1982) Specific Killing Effect of 10B1-Para-boronophenylalanine in Thermal Neutron Capture Therapy of Malignant Melanoma, in Vitro Radiobiological Evaluation. Journal of Investigative Dermatology, 78, 215-218.  
https://doi.org/10.1111/1523-1747.ep12506489</mixed-citation></ref><ref id="scirp.97500-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hiratsuka, J., et al. (1982) RBEs of Thermal Neutron Capture Therapy and 10B(n, alpha)7Li Reaction on Melanoma Bearing Hamsters. Pigment Cell Research, 2, 352-355. https://doi.org/10.1111/j.1600-0749.1989.tb00219.x</mixed-citation></ref><ref id="scirp.97500-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Matsusaki, M. (2012) Development of Three-Dimensional Tissue Models Based on Hierarchical Cell Manipulation Using Nanofilms. Bulletin of the Chemical Society of Japan, 85, 401-414. https://doi.org/10.1246/bcsj.20110194</mixed-citation></ref><ref id="scirp.97500-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Matsusaki, M., Case, C.P. and Akashi, M. (2014) Three-Dimensional Cell Culture Technique and Pathophysiology. Advanced Drug Delivery Reviews, 74, 95-103.  
https://doi.org/10.1016/j.addr.2014.01.003</mixed-citation></ref><ref id="scirp.97500-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Asano, Y., Odagiri, T., Oikiri, H., Matsusaki, M., Alashi, M. and Shimoda, H. (2017) Construction of Artificial Human Peritoneal Tissue by Cell-Accumulation Technique and Its Application for Visualizing Morphological Dynamics of Cancer Peritoneal Metastasis. Biochemical and Biophysical Research Communications, 494, 213-219. https://doi.org/10.1016/j.bbrc.2017.10.050</mixed-citation></ref><ref id="scirp.97500-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nishiguchi, A., Matsusaki, M., Kano, M.R., Nishihara, H., Okano, D., Asano, Y., Shimoda, H., Kishimoto, S., Iwai, S. and Akashi, M. (2018) In Vitro 3D Blood/ Lymph-Vascularized Human Stromal Tissues for Preclinical Assays of Cancer Metastasis. Biomaterials, 179, 144-155.  
https://doi.org/10.1016/j.biomaterials.2018.06.019</mixed-citation></ref><ref id="scirp.97500-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Tan, M.H., Nowak, N.J. and Loor, R. (1986) Characterization of a New Primary Human Pancreatic Tumor Line. Cancer Investigation, 4, 15-23.  
https://doi.org/10.3109/07357908609039823</mixed-citation></ref><ref id="scirp.97500-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Deer, E.L., Hernandes, J.G., Coursen, J.D., Shear, J.E., et al. (2010) Phenotype and Genotype of Pancreatic Cancer Cell Lines. Pancreas, 39, 425-435.  
https://doi.org/10.1097/MPA.0b013e3181c15963</mixed-citation></ref></ref-list></back></article>